Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

NCT06516289 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

BRCA-Mutated Breast Carcinoma
HER2-negative Breast Cancer

Interventions

DRUG: HRS-1167
DRUG: Famitinib
DRUG: Camrelizumab

Sponsor

Fudan University